News Release: Hemedex, Inc. Receives CE Mark for the QFlow 500™ Single Lumen and Dual Lumen Titanium Bolt Kits

Posted by on Feb 12, 2014 in News Releases

News Release: Hemedex, Inc. Receives CE Mark for the QFlow 500™ Single Lumen and Dual Lumen Titanium Bolt Kits

CAMBRIDGE, Mass. (February 2, 2014) – Hemedex, Inc. is pleased to announce the receipt of the CE Mark for their QFlow 500™ Single Lumen and Dual Lumen Titanium Bolt Kits. This regulatory approval enables Hemedex to sell these products in Europe and other international countries that accept CE Mark for regulatory approval.

The QFlow 500™ Titanium Bolt Kits secure the minimally invasive QFlow 500™ Perfusion Probe through a burr hole in the cranium.  The Hemedex Titanium Bolt Kits are the optimal solution for a user that seeks a single or dual access port.  Both bolts are made with titanium bodies, are CT compatible, and are easy to place requiring no additional tools to insert or remove the bolt other than a drill.

SL Bolt Kit on Black 675x460 Better

The QFlow 500™ Titanium Bolt Kit-Single Lumen includes a single lumen bolt, 2.7mm drill bit, hex wrench and depth collar.

 

DL Bolt Kit on Black 675x460

The QFlow 500™ Titanium Bolt Kit-Dual Lumen includes a dual lumen bolt, 5.3mm drill bit, hex wrench, and depth collar.

Hemedex also sells the bolts and drill bits separate from the kit if desired.  For pricing and order information please contact salesteam@hemedex.com.  For more information on the bolts please visit http://hemedex.com/products/overview/.

 

About Hemedex, Inc.:

Hemedex, Inc. manufactures patient monitoring technology, the Bowman Perfusion Monitor®, for quantifying tissue blood flow. The Company’s patented technology provides clinicians with a powerful tool, which can provide an early warning of compromised blood flow and help target appropriate therapies rapidly and accurately. Data from the Bowman Perfusion Monitor helps guide physicians in implementing effective treatments quickly, creating the potential to improve patient outcomes and lower costs. Hemedex’s technology addresses unmet needs in many clinical areas such as neurocritical care (e.g., TBI, SAH), neurosurgery (e.g., TAO, EC-IC Bypass, Moya Moya), reconstructive surgery and organ transplantation, among others.  For more information, visit www.hemedex.com.

Communications Team
Hemedex Inc.
sblair@hemedex.com
617 577 1759 X 46